FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
The key to fibrinolysis and thrombolysis
1684PDF: 518HTML: 260 -
Anticoagulation in obese patients: challenges and strategies
2021PDF: 520HTML: 302XML: 185 -
-
PO64 | A silent hemorrhage in the immuno-thrombotic chaos of antiphospholipid syndrome G. Autiero, S.A. Malerba, A. Malaguti, M. Dalla Vestra, F. Presotto | Medicina Generale, Ospedale dell’Angelo, Mestre-Venezia, Italy
651PDF: 16 -
CO-71 | ACQUIRED FACTOR XIII DEFICIENCY IN A PATIENT POST-CAR-T THERAPY FOR NON-HODGKIN LYMPHOMA: A CASE REPORT A. Strangio, M. Leotta, A. Ierardi, R.C. Santoro | Hemophilia, Hemostasis and Thrombosis Unit, Azienda Ospedaliero Universitaria Renato Dulbecco, Catanzaro, Italy
22PDF: 3 -
PO30 | LONG-TERM ANTICOAGULANT THERAPY AND PREVENTION OF RECURRENT VENOUS THROMBOEMBOLISM IN ADVANCED OVARIAN CANCER V. Bitsadze 1, A. Vorobev 1, J. Khizroeva 1, A. Solopova 1, M. Tretyakova 1, N. Gashimova 1, K. Grigoreva 1, A. Khisamieva 1, J. Gris 1|2, I. Elalamy1|3|4, G. Gerotziafas1|3|4, A. Makatsariya1 | 1Department of Obstetrics, Gynecology and Perinatal Medicine, N. F. Filatov Clinical Institute of Children’s Health, I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 2Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France; 3Department Hematology and Thrombosis Center, Medicine Sorbonne University, Paris, France; 4Hospital Tenon, Paris, France
457PDF: 97 -
PO82 | Retrospective application of the TH2 score in a multicenter cohort of ITP patients: a reliable predictive tool or a score in need of refinement? C. Giubbilei1, M. Defina2, S. Rosati3, M. Rocco3, A. Votto4, F. Simonetti5, F. Paoletti6, V. Carrai1 | 1Hematology Unit, AOU Careggi; 2Hematology unit AOU Senese; 3Hematology Unit Azienda Sanitaria Toscana Centro; 4Hematology Unit, AOU Pisana; 5Hematology Unit, Ospedale Versilia; 6Hematology Unit, Azienda Sanitaria Nord Ovest, Italy
561PDF: 16 -
Development of a shared decision-making tool for gene therapy in hemophilia A in Italy
916PDF: 131SUPPLEMENTARY MATERIAL: 78 -
PO86 | Emicizumab in patients with moderate hemophilia A and severe bleeding phenotype: single-center real-world experience A.L. Faccini, M. Biglietto, S. Sorella, E. Crisanti, M. Antonacci, R. Mormile, R. Ciciani, E. Baldacci, C. Santoro, S. Ligia | Hematology, Department of Translational and Precision Medicine Sapienza University of Roma, Italy
740PDF: 23 -
PO39 | RISK OF VENOUS THROMBOEMBOLISM ASSOCIATED WITH PERIPHERALLY INSERTED CENTRAL CATHETERS IN CANCER PATIENTS RECEIVING CHEMOTHERAPY: A REAL-WORLD SINGLE-CENTRE EXPERIENCE S. Gilani, H. Rubbani, A. Mackie | Cancer Centre, University Hospitals of North Midlands, Staffordshire, UK
489PDF: 108 -
PO92 | Challenging management of portal vein thrombosis in a cirrhotic patient on hormone therapy after breast cancer L. Jr Valletta, C. De Luca, M. Aversano, C. Caputo, E. Cimino, P. Conca, A. Tufano, M.D. Di Minno | AOU Federico II Napoli, Italy
562PDF: 16 -
Clinical characteristics, prescription patterns and clinical outcomes of patients with extended therapy with direct oral anticoagulants for unprovoked venous thromboembolism Insights from the RIETE Registry
1322PDF: 125SUPPLEMENTARY FILES: 89APPENDIX: 107 -
CO07 | Real word management of anticoagulant therapy in brain metastasis: moving toward a multidisciplinary approach in complex cases E. Lotti1, C. Manneschi2, S. Fancelli2, F. Scolari1, F. Crudele1, D. Poli1, M. Berteotti1, D. Rossini3, S. Pillozzi2, L. Antonuzzo2,3, R. Marcucci1,3 | 1Disease Unit, Careggi University Hospital, Firenze; 2Oncology Unit, Careggi University Hospital, Firenze; <sup>3</sup>Department of Experimental and Clinical Biomedical Sciences, University of Firenze, Italy
616PDF: 20 -
PO91 | Disseminated intravascular coagulation with deep vein thrombosis in a frail patient: an extreme manifestation triggered by sepsis during SGLT2i therapy M. Vacca1, M.V. Cherchi1, S. Che1, G.A.M.L. Costanzo2, D. Firinu2, M. Mantega1, S. Del Giacco2 | 1Ospedale Sirai, ASL Sulcis, 2Università degli Studi di Cagliari, Italy
790PDF: 17 -
PO96 | Patient management with arteriovenous thrombotic manifestation and hemorrhagic complications M. Aversano, E. Cimino, L. Jr Valletta, C. Caputo, M. Romeo, M.D. Di Minno, A. Tufano, I.L. Calcaterra, C. De Luca, R. Russo, G. D’errico, P. Conca | Università degli Studi Federico II, Napoli, Italy
585PDF: 11 -
Still unmet problems with low molecular weight heparin prophylaxis of venous thromboembolism. An Italian survey
1441PDF: 302HTML: 201Supplementary: 102 -
PO16 | Antithrombotic treatment and outcomes in retinal vein occlusion: a retrospective cohort study and comparison with historical group S.A. Malerba1,2, M.T. Sartori1, G. Libralon1, C. Dalla Porta1, P. Simioni1 | 1First Medical Clinic, Department of medicine- DIMED, Università degli Studi di Padova; 2Medicina Generale, Ospedale dell’Angelo, Mestre, Italy
606PDF: 11 -
PO29 | Quality of anticoagulation as a predictor of early left ventricular thrombosis resolution: a retrospective cohort study A. Pannunzio1, I.M. Palumbo1, M.P. Donadini2, D. Santagata2, W. Ageno2, F. Dragoni3, A. Chistolini3, C. Becattini4, K. Satula4, D. Menichelli1, D. Pastori1, P. Pignatelli5, E. Valeriani1 | 1Department of General Surgery and Surgical Specialty Paride Stefanini, Sapienza University of Roma; 2Department of Medicine and Surgery, University of Insubria, Varese; 3Hematology, Department of Translational and Precision Medicine, Sapienza University of Roma; 4Internal Vascular and Emergency Medicine - Stroke Unit, University of Perugia; 5Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Roma, Italy
602PDF: 14 -
PO36 | Venous stenting for symptomatic iliac thrombosis: five-years experience of single center I. Nichele1, G. Marchesini1, L. Boi2, G. Carli1, A. Tosetto1 | 1Hemophilia and Thrombosis Center, Hematology Department, S. Bortolo Hospital, Vicenza; 2Radiology Department, Ospedale Ca’ Foncello, Treviso, Italy
620PDF: 24 -
PO49 | PROPHYLACTIC ANTICOAGULATION DECISIONS IN HIGH-RISK PATIENTS RECEIVING CANCER-DIRECTED THERAPY: ANALYSIS OF THE VERMONT METHOD J. Barker1, K. Libby1, C. Holmes2, K. Martin2 | 1University of Vermont Health System; 2Department of Medicine, University of Vermont, Burlington, VT, USA
442PDF: 102 -
PO14 | Searching for safer rescue immunosuppressive therapy protocols in acquired hemophilia A: two case reports G. Quintavalle1, I.M. Tassoni1, B.M. Roccon1, G. Lucchini2, F. Magalini2, M. Zardo2, R. Rossi3, C. Cattabiani3, A. Tagliaferri1, A. Coppola1 | 1SSD Centro HUB Emofilia e MEC; 2UOS Medicina Interna e Reumatologia; 3UO Diagnostica Ematochimica, Azienda Ospedaliero Universitaria, Parma, Italy
548PDF: 17 -
PO67 | Pancreatic cancer in a 71-year-old severe hemophilia A patient with inhibitors and sustained zero bleeding during emicizumab prophylaxis M. Biglietto, A.L. Faccini, S. Sorella, E. Crisanti, M. Antonacci, A. Taglietti, M. Gherardini, A. Tirnetta, S. Ligia, R. Mormile, R. Ciciani, E. Baldacci, C. Santoro | Hematology, Department of Translational and Precision Medicine Sapienza University of Roma, Italy
655PDF: 26 -
PO44 | Emicizumab in acquired haemophilia A M. Leotta, A. Strangio, A. Ierardi, S. Prejanò, R C. Santoro | Hemostasis and Thrombosis Unit, Department Hemato-Oncology, Azienda Ospedaliero-Universitaria Renato; Dulbecco, Catanzaro, Italy
618PDF: 19 -
PO31 | Comparative analysis of anticoagulant therapy in patients over 90 years old: vitamin K antagonists versus direct oral anticoagulants G. Sottilotta1, P. Arrigo2, S. Cuzzocrea1, D. Megalizzi1, F. Luise3 | 1UOSD Microcitemie, Emostasi e Trombosi, Grande Ospedale Metropolitano di Reggio Calabria; 2Associazione Italiana Pazienti Anticoagulati, Sezione di Reggio Calabria; 3Laboratorio Analisi. Grande Ospedale Metropolitano di Reggio Calabria, Italy
590PDF: 15 -
PO56 | Safety of anticoagulant treatment in patients with splanchnic vein thrombosis and history of portal hypertension-related bleeding R. Talerico1, S. Pellegrino1, A. Plessier2, F.R. Ponziani3, A. Porfidia1, F. Landi1, A. Gasbarrini3, R. Pola1, F. Santopaolo3 | 1Department of Geriatric, Orthopedic, and Rheumatologic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy; 2Université de Paris, AP-HP, C, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVE. Centre de recherche sur l’inflammation, Inserm, Paris, France; 3Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy
605PDF: 18 -
CO-78 | REAL-WORLD MANAGEMENT OF ACQUIRED HEMOPHILIA A: FOCUS ON RECOMBINANT PORCINE FVIII AS FIRST-LINE HEMOSTATIC TREATMENT AND LONG-TERM OUTCOMES M. Leotta, A. Strangio, A. Ierardi, R.C. Santoro | Hemophilia, Hemostasis and Thrombosis Centre, Azienda Ospedaliero Universitaria Renato Dulbecco, Catanzaro, Italy
17PDF: 4 -
CO-42 | LONGITUDINAL THROMBIN GENERATION PROFILING IN A PATIENT WITH SEVERE HEMOPHILIA A DURING ANTITHROMBIN-LOWERING THERAPY, CANCER, AND MAJOR SURGERY C. Simion1|2, C. Bulato1, E. Campello1|2, E. Zanon1|2, B. Serena1, S. Toffanin1, P. Simioni1|2 | 1First Chair of Internal Medicine and Thrombotic and Haemorrhagic Diseases Unit, Department of Medicine, Padova University Hospital, Italy; 2Hemophilia Center, Padova University Hospital, Italy
18PDF: 2 -
CO11 | Oral anticoagulation with vitamin K antagonists in early childhood: a single centre-experience B. Borsellino1,2, B. Pollio1, I. Ricca1, R. Albiani1, T. Martini1 | 1Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Torino; 2Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Roma Tor Vergata, Roma, Italy
704PDF: 23 -
PO90 | Acquired hemophilia A with high-titer inhibitor in a patient with cardiovascular and metabolic comorbidities M.G. Mazzone, G. Chiarelli, R. Russo, L. Valletta Jr, G. D’Errico, C. De Luca, P. Rufolo, A. Tufano, E. Cimino, P. Conca, M.N.D. Di Minno | Department of Clinical Medicine and Surgery, Federico II University of Naples, Italy
654PDF: 25 -
CO23 | Markers of inflammation and hypofibrinolysis are associated with cognitive dysfunction and motor performances in atrial fibrillation patients on oral anticoagulant therapy: insights from the Strat-AF study F. Alfano1,2, F. Cesari1,2, A.M. Gori1,2, M. Berteotti1,2, E. Salvadori3, B. Giusti1,2, A. Bertelli1,2, F. Fratini4, A. Rogolino1,2, B. Formelli4,5, F. Pescini4,5, E. Fainardi6, E. Barucci4, G. Salti5, A. Cavaliere4, A. Ginestroni6, A. Poggesi4,5, R. Marcucci1,2 | 1Department of Experimental and Clinical Medicine, University of Firenze; 2Center for Atherothrombotic Diseases, Careggi University Hospital, Firenze; 3Department of Biomedical and Clinical Sciences, University of Milan; 4NEUROFARBA Department, Neuroscience Section, University of Firenze; 5Stroke Unit, Careggi University Hospital, Firenze; 6Neuroradiology Unit, Careggi University Hospital, Department of Experimental and Clinical Biomedical Sciences, University of Firenze, Italy
720PDF: 23 -
PO72 | Fondaparinux in patient with active tuberculosis T. Marrazzo1, R. Parrella2, A. Botta2, A. Pontarelli2, M.P. Ursi3, A. Karruli4, R. Albisinni5 | 1UOC Medicina Interna e dei Trapianti, Ospedale Monaldi, Napoli, Italy; 2UOC Malattie Infettive ad Indirizzo Respiratorio, Ospedale Cotugno Azienda dei Colli, Napoli, Italy; 3UOC MECAU Ospedale CTO Azienda dei Colli, Napoli, Italy; 4Malattie Infettive e Tropicali, Ospedale di Tirana, Albania; 5UOC CCH Generale, Ospedale Monaldi Azienda dei Colli, Napoli, Italy
626PDF: 16 -
PO18 | THE THROMBO-INFLAMMATION AXIS AS PREDICTOR OF TOXICITY IN PATIENTS TREATED WITH CAR-T CELLS C. Fernández-Arias1, M. Marcos-Jubilar1, M. Panizo1, C. Vázquez-Puerta2, J.R. González-Porras2, M. Ibáñez1, A. Queralt1, M. Carrasco1, M.B. Villacrés1, C. Conde1, P. Elizalde1, S. Huerga1, A. Alfonso1, P. Rodríguez-Otero1, S. Villar1, M.A. Canales1, J. Rifón1, F. Prósper1, J.A. Páramo1, J. Orbe1, R. Lecumberri1 | 1Clínica Universidad de Navarra, Pamplona; 2Hospital Clínico Universitario de Salamanca, Salamanca, Spain
508PDF: 88 -
PO13 | Monitoring of anti-factor XA activity levels in patients treated with direct oral anticoagulants and concomitant tyrosine kinase inhibitors agents: a monocentric experience E. Santacroce1,2, C. Santoro1, E. Baldacci1, S. Ligia1, R. Mormile1, M. Biglietto1, M. Totaro1, F. R. Mauro1, M. Breccia1, A. Chistolini1 | 1Department of Translational and Precision Medicine, Haematology, Sapienza University of Roma; 2Department of Clinical and Molecular Medicine, Sapienza University of Roma, Italy
639PDF: 18 -
CO21 | Viscoelastic testing in inherited bleeding disorders: a cross-sectional comparison between viscoelastic coagulation monitoring and rotational thromboelastometry C. Simion, C. Samà, C. Bulato, G. Gottardi, D. Regazzo, E. Campello, P. Simioni | Department of Medicine – DIMED, University of Padua, Italy
638PDF: 17 -
PO64 | MANAGEMENT OF BLEEDING RISK IN PATIENTS WITH HEPATOCELLULAR CARCINOMA RECEIVING SYSTEMIC THERAPY: A SURVEY OF CLINICAL PRACTICE T. Van Broeckhoven1|9, E. Van Gansewinkel5|10, J. De Bruijne2, F. Eskens3, D. De Groot4, K. Hermans5, N. Mohammad6, F. Van Vilsteren7, C. Verslype8, W. Moris9, M. Roest10, B. De Laat10 , J. De Vos-Geelen5, M. Kramer1|9 | 1Department of Gastroenterology and Hepatology, GROW – Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands; 2Department of Gastroenterology & Hepatology, Utrecht University, University Medical Center Utrecht, The Netherlands; 3Department of Medical Oncology, Erasmus Medical Centre, Rotterdam, the Netherlands; 4Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, the Netherlands; 5Department of Internal Medicine, Division of Medical Oncology, GROW – Research Institute for Oncology & Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands; 6Department of Medical Oncology, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands; 7Department of Gastroenterology and Hepatology, University Medical Centre Groningen, Groningen, The Netherlands; 8Digestive Oncology, University Hospitals Leuven, Belgium; 9Department of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands; 10Department of Functional Coagulation, Synapse Research Institute, Maastricht, The Netherlands, on behalf of the Dutch Hepatocellular & Cholangiocarcinoma Group
435PDF: 95 -
CO-31 | WHEN NECK PAIN HIDES A SPINAL BLEED: ANTERIOR CERVICAL EPIDURAL HEMATOMA IN A CHILD WITH HEMOPHILIA B E. Dalla Porta, C. Simion, E. Zanon, B. Stocco, L. Spiezia, P. Simioni | Hemophilia Center, University Hospital of Padua, Italy
19PDF: 4 -
PO11 | THROMBOEMBOLIC EVENTS DURING PERIOPERATIVE THERAPY FOR RESECTABLE AND BORDERLINE RESECTABLE PANCREATIC CANCER IN THE PREOPANC-2 TRIAL R.A.L. Willems1|5, A.E. Van Diepen1|2|6, EN. Dekker7, Q.P. Janssen7, J.L. Van Dam7, N. Michiels8, C.W.F. Van Eijck9, K.E.P.E. Hermans1|2, B.A. Bonsing8, K.P. Bosscha10, S.A.W. Bouwense11|12, O. R. Busch13|14, H. Ten Cate4|5|15|16, P.P.L.O. Coene17, C.H.J. Van Eijck7, N. Van Es18|19, E. Van Der Harst17, I.H.J.T. De Hingh20, T.M. Karsten21, G. Kazemier13|14, M.B. Van Der Kolk22, B. De Laat3|5, M.S.L. Liem22, J.S.D. Mieog8, V.B. Nieuwenhuijs24, G.A. Patijn24, M. Roest3, H.C. Van Santvoort25, L. Valkenburg-Van Iersel1|2, R. F. De Wilde7, F. Wit26, B.M. Zonderhuis13|14, M.G. Besselink13|14, M.Y.V. Homs6, G. Van Tienhoven14|27, J. W. Wilmink14|28, B. Groot Koerkamp7, J. De Vos-Geelen1|2 | 1Maastricht University Medical Center, Department of Internal Medicine, Division of Medical Oncology; 2GROW – Research Institute for Oncology & Reproduction, Maastricht University, Maastricht; 3Synapse Research Institute, Department of Functional Coagulation, Maastricht; 4Maastricht University Medical Center, Thrombosis Expert Center Maastricht, Maastricht; 5Maastricht University Medical Center, Cardiovascular Research Institute Maastricht (CARIM), School for Cardiovascular Diseases, Maastricht; 6Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam; 7Erasmus MC Cancer Institute Rotterdam, University Medical Center Rotterdam, Department of Surgery; 8Leiden University Medical Center, Department of Surgery, Leiden; 9Solid Tumour Immunology Research Rotterdam (STIRR), Department of Pulmonary Medicine, Erasmus University Medical Centre, Rotterdam; 10Jeroen Bosch Hospital, Department of Surgery, Den Bosch; 11Maastricht University Medical Center, Department of Surgery, Maastricht; 12Maastricht University Medical Center, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht; 13Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam; 14Cancer Center Amsterdam; 15Maastricht University Medical Center, Department of Internal Medicine, Division Vascular Medicine, Maastricht; 16Maastricht University, Department of Biochemistry, Laboratory for Clinical Thrombosis and Hemostasis, Maastricht; 17Maasstad Hospital, Department of Surgery, Rotterdam; 18Amsterdam UMC, location University of Amsterdam, Department of Vascular Medicine, Amsterdam; 19Amsterdam UMC, location University of Amsterdam, Amsterdam Cardiovascular Sciences, Pulmonary Hypertension & Thrombosis, Amsterdam; 20Catharina Hospital, Department of Surgery, Eindhoven; 21OLVG, Department of Surgery, Amsterdam; 22Radboud University Medical Center, Department of Surgery, Nijmegen; 23Medisch Spectrum Twente, Department of Surgery, Enschede; 24Isala Oncology Center, Department of Surgery, Zwolle; 25Regional Academic Cancer Center Utrecht, St. Antonius Hospital and University Medical Center Utrecht, Department of Surgery, Utrecht; 26Frisius MC, location Leeuwarden, Department of Surgery, Leeuwarden; 27Amsterdam UMC, location University of Amsterdam, Department of Radiation Oncology, Amsterdam; 28Amsterdam UMC, location University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands
423PDF: 89 -
PO34 | A negative oncologic follow up doesn’t always really mean no cancer: two case report of cancer-associated thrombotic microangiopathy E. Cosi, A. Bertomoro, G. Bogoni, I. Bertozzi, I. Cortella, P. Simioni | Clinica Medica ORI, Azienda Ospedale-Università Padova, DIDAS, Italy
585PDF: 22 -
CO19 | Hypercoagulability in wild-type transthyretin amyloidosis: evidence from whole blood thromboelastometry A. Napolitano1, L. Spiezia1, C. Samà1, A. Benetti1, G. Sinigiani2, L. De Michieli2, A. Cipriani2, P. Simioni1 | 1First Chair of Internal Medicine, Department of Medicine, University Hospital of Padua; 2Department of Cardiothoracic and Vascular Sciences & Public Health, University Hospital of Padua, Italy
588PDF: 10 -
PO27 | B-cell lymphoproliferative disorder and acquired coagulopathy: an insidious link C. Caputo, P. Conca, I.L. Calcaterra, E. Cimino, M. Romeo, M. Aversano, E. Franco, C. De Luca, R. Russo, C. Fierarossa, M.N.D. Di Minno, A. Tufano | Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy
612PDF: 14 -
PO77 | The clinical awareness of mixing test interpretation in the era of complex reporting algorithm: do we forget the origins? A. Fassina, L. De Valentin, S. Luzi, R. Turrini, A. Antico, L. Zardo | Laboratorio Analisi Castelfranco Veneto, ULSS Marca Trevigiana, Italy
625PDF: 15 -
PO59 | Efficacy and safety of different anticoagulant treatment regimens for isolated internal jugular vein thrombosis: a case series A. Pannunzio1, E. Valeriani1, I.M. Palumbo1, S. Marucci2, D. Menichelli1, D. Pastori2, P. Pignatelli2 | 1Department of General Surgery and Surgical Specialty, Sapienza University of Roma; 2Department of Clinical, Internal Medicine, Anaesthesiological and Cardiovascular Sciences, Sapienza University of Roma, Italy
686PDF: 29 -
PO22 | LONG-TERM ANTICOAGULANT THERAPY AND REDUCTION OF OVARIAN CANCER RECURRENCE: CLINICAL EVIDENCE OF A POTENTIAL ANTITUMOUR EFFECT J. Khizroeva1, V. Bitsadze1, A. Vorobev1, A. Solopova1, M. Tretyakova1, N. Gashimova1, K. Grigoreva1, A. Khisamieva1, J. Gris1|2, I. Elalamy1|3|4, G. Gerotziafas1|3|4, A. Makatsariya1 | 1Department of Obstetrics, Gynecology and Perinatal Medicine, N. F. Filatov Clinical Institute of Children’s Health, I. M. Sechenov First Moscow State Medical University, Moscow, Russia; 2Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France; 3Department Hematology and Thrombosis Center, Medicine Sorbonne University, Paris, France; 4Hospital Tenon, Paris, France
411PDF: 88 -
PO49 | Use of emicizumab in two patients with acquired hemophilia A: a new therapeutic approach S. Sorella, J. Micozzi, E. Baldacci, M. Biglietto, R. Mormile, A. Chistolini, R. Ciciani, L. Torrieri, N. Zhdanovskaya, M. Lorenzon, A. Delli Paoli, S. Ligia, C. Santoro | Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University of Roma, Italy
654PDF: 23 -
Bleeding complications of oral anticoagulant therapy: from ISCOAT to the START Register A memory of Gualtiero Palareti
1716PDF: 238 -
BEST-10 | CHANGES IN HYPERTROPHIC SYNOVIUM STATUS IN ADULT PATIENTS WITH SEVERE HEMOPHILIA A RECEIVING EMICIZUMAB PROPHYLAXIS: THE RESOLVE STUDY I.L. Calcaterra1, M. Di Minno1, E. Baldacci2, G. D’Errico1, C. Santoro2, A. Strangio3, S. Sorella2, M. Leotta3, R.C. Santoro3 | 1Department of Clinical Medicine and Surgery, Federico II University, Napoli, Italy; 2Haematology, University Hospital Policlinico Umberto I, Roma, Italy; 3Hemostasis and Thrombosis Centre, Azienda Ospedaliero Universitaria Renato Dulbecco, Catanzaro, Italy
39PDF: 8 -
CO15 | Longitudinal coagulation profiling of individuals undergoing gender-affirming hormone therapy: the hyper-gender study A. Napolitano, E. Campello, A. Scala, C. Simion, C. Bulato, S. Gavasso, C. Samà, A. Benetti, S. Toffanin, G. Faggian, R. Scafa, A. Garolla, P. Simioni | First Chair of Internal Medicine, Department of Medicine, University Hospital of Padua; Unit of Andrology and Reproductive Medicine, Department of Medicine, University Hospital of Padua, Italy
662PDF: 18 -
PO66 | Viscoelastic tests in disseminated intravascular coagulation associated with aortic aneurysm A. M. Pizzini1, C. Biasoli2, M. Bovara3, E. Gesuete1, A. Fusco1, C. Fantoni1, P. Pedrazzi2, R. Mancini3, M. Silingardi1 | 1Ambulatorio Emostasi & Trombosi, Dipartimento Medico, Ospedale Maggiore AUSL Bologna; 2SSI Presa in Carico delle Malattie Emorragiche e Tromboemboliche della Romagna; 3Laboratorio Unico Metropolitano AUSL Bologna, Italy
638PDF: 17 -
The evolving landscape of gene therapy for congenital severe hemophilia: a 2024 state of the art
2074PDF: 359SUPPLEMENTARY MATERIAL: 217 -
CO12 | Left internal carotid artery thrombosis in a patient with antiphospholipid antibody syndrome successfully treated with eculizumab A. Hoxha1, L. Nico2, F. Viaro3, L. Fabris1, Y.F. Herrera1, M. Munari4, C. Baracchini3, F. Causin2, P. Simioni1 | 1Internal Medicine Unit, Thrombotic and Haemorrhagic Centre, Department of Medicine - DIMED, University of Padua; 2Neuradiology Unit, University Hospital of Padua; 3Stroke Unit, Neurology Department, University of Padua; 4Intensive Care Unit, University Hospital of Padua, Italy
675PDF: 21 -
PO65 | Utilization of emicizumab in acquired hemophilia A: a case report C. Caputo, P. Conca, I.L. Calcaterra, E. Cimino, M. Romeo, M. Aversano, E. Franco, C. De Luca, G. D’errico, L. Jr Valletta, M. Di Minno, A. Tufano | Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy
615PDF: 23 -
PO83 | A case of deep vein thrombosis in a patient with systemic mastocytosis M. Leotta, A. Ierardi, A. Strangio, R C. Santoro | UO Emofilia, Emostasi e Trombosi, AOU R Dulbecco, Catanzaro
746PDF: 21 -
CO-61 | REAL-WORLD IMPLEMENTATION OF GENE THERAPY FOR HEMOPHILIA: A SHARED PATHWAY AMONG HEALTHCARE AUTHORITY, SPECIALIST CENTERS AND PATIENT ORGANIZATIONS IN THE EMILIA-ROMAGNA REGION A. Coppola1, L. Valdrè2, C. Biasoli3, E. Ferri Grazzi4, E. Rozzi5, M. Volta5, R. Giroldini6, A. Tagliaferri1 | 1SSD Centro Hub Emofilia e Malattie Emorragiche Congenite, Azienda Ospedaliero-Universitaria di Parma, Italy; 2SSD Malattie Emorragiche Congenite, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy; 3SSI Presa in Carico delle Malattie Emorragiche e Tromboemboliche, AUSL Romagna, Ospedale Bufalini, Cesena, Italy; 4FEDRED, Federazione delle Associazioni Emofilici della Regione Emilia Romagna, Italy; 5Servizio Assistenza Ospedaliera, Malattie Rare, Direzione Generale Cura della Persona, Salute e Welfare, Regione Emilia Romagna, Italy; 6Area Governo del Farmaco e Dispositivi Medici, Direzione Generale Cura della Persona, Salute e Welfare, Regione Emilia Romagna, Italy
13PDF: 4 -
OC09 | BLEEDING RISK ASSOCIATED WITH FACTOR XI MONOCLONAL ANTIBODIES IN COMBINATION WITH ASPIRIN IN HEALTHY VOLUNTEERS AND ORTHOPEDIC SURGERY PATIENTS: ANALYSIS FROM RECENT PHASE 1 AND PHASE 2 STUDIES A.P. Kithcart1, M.E. Burczynski1, P. Banerjee1, M. Onisko1, Y. Wang1, K. Mohammadi1, D. Li1, S. Li1, J. Ackroyd2, B.A. Olenchock1, D.E. Gutstein1, J. I. Weitz3 | 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 2Clinical Research, Fortrea Clinical Research Unit Ltd, Leeds, UK; 3McMaster University, Hamilton, ON, Canada
441PDF: 113 -
CO-32 | TRAUMA MANAGEMENT IN SEVERE HEMOPHILIA A: A CASE REPORT J. Di Paolo, R. Malizia, M. Luongo, P. Massaro, M. Di Mascio, S. Verna | Immunohematology Service, ASL 02 Abruzzo, Chieti, Italy
16PDF: 2 -
CO33 | Acquired hemophilia A in Liguria, Italy: what six years of data reveal C. Vernarecci1, A. C. Molinari1, P. Ballarino2, M. Caiti2, E. Cenni2, P. Moscatelli2, L. Banov1 | 1IRCCS Istituto Giannina Gaslini, Genova; 2IRCCS Policlinico San Martino, Genova, Italy
605PDF: 28 -
CO-59 | CONCIZUMAB IN A YOUNG CHILD WITH SEVERE HEMOPHILIA B WITH INHIBITOR: EFFECTIVE BLEED CONTROL AND SAFE HOME MANAGEMENT T. Martini1, B. Borsellino1|2, B. Pollio1 | 1Hemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Torino, Italy; 2Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Roma, Italy
22PDF: 4 -
OC05 | TIME TO START OF ANTICOAGULANT THERAPY AND SURVIVAL OUTCOMES IN CANCER PATIENTS WITH PULMONARY EMBOLISM K. Bria, B. Gage, M. Bealsey, K. Sanfilippo | Washington University in St. Louis School of Medicine, St. Louis, MO, USA
492PDF: 106 -
CO32 | Major surgery in patients with severe hemophilia A without inhibitors receiving prophylaxis with fitusiran E. Zanon, C. Simion, A. Napolitano, L. Spiezia, P. Simioni | Haemophilia Center, First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy
552PDF: 21 -
PO80 | Heparin-induced thrombocytopenia: a monocentric experience with danaparoid L. D’Innocenzo, S. Sorrentino, M. De Siati, A. Ferretti, E. De Candia | Unit of Haemostasis and Thrombosis Diseases, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma, Italy
688PDF: 12 -
CO-56 | EVALUATING AN AI MODEL’S HEMATOLOGY CONSULTATION PERFORMANCE FOR HOSPITALIZED PATIENTS WITH BLEEDING DISORDERS G. Sottilotta1, F. Misiti2, G. Praticò1, D. Megalizzi1, F. Luise3 | 1UOSD Microcitemie - Emostasi e Trombosi. Grande Ospedale Metropolitano di Reggio Calabria, Italy; 2Associazione Emofilici di Reggio Calabria, Italy; 3Laboratorio Analisi. Grande Ospedale Metropolitano di Reggio Calabria, Italy
20PDF: 5 -
PO47 | VENOUS THROMBOEMBOLISM IN BREAST CANCER: INSIGHTS FROM A SINGLE-CENTER COHORT S. Kozhukhov, N. Dovganych | SI “NSC “The M. D. Strazhesko Institute of Cardiology, Clinical and Regenerative Medicine of the National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine; 2Cardio-Oncology Center, Kyiv, Ukraine
471PDF: 109 -
PO23 | IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA RELATED TO DELAYED IMMUNE CHECKPOINT INHIBITORS TOXICITY: A CASE REPORT E. Galimberti1, F. Schieppati1, C. Ambaglio1, M. Marchetti1, L. Barcella1, A. Falanga1|2 | 1Immunohematology and Transfusion Medicine Unit, ASST Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milan-Bicocca, Milano, Italy
401PDF: 84 -
OC03 | THROMBOEMBOLIC PREVALENCE IN MULTIPLE MYELOMA BEFORE AND AFTER THE INTRODUCTION OF DIRECT ORAL ANTICOAGULANTS: A LONGITUDINAL COHORT STUDY A. Ramírez1, A. Orozco2, A. Sánchez3, F. Villalpa1, S. Burgos2, G. Cesarman3, G. Rodríguez1, D. Vieyra2, J. Álvarez4, G.M. Flores3, S. González1, D. Martínez2, B. Cabello3, R. Espinoza3, O. Fernández3 | 1Myeloma-clinic Hematology service, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, México City, México; 2Myeloma-clinic Hematology service, Instituto Nacional de Nutrición Salvador Zubirán, México City, México; 3Myeloma-clinic Hematology service, Instituto Nacional de Cancerologçia, México City, Mexico; 4Centro Médico Nacional 20 de Noviembre, México City, Mexico
484PDF: 104 -
PO62 | CLINICAL AND MOLECULAR DIAGNOSTIC CHALLENGES IN MYELOPROLIFERATIVE NEOPLASMS WITH LOW JAK2V617F ALLELIC BURDEN E. Morsia, D. Lame, M. Pianelli, G. Gramazio, R. Ceccarelli, I. Battilà, S. Rupoli, A. Poloni | Department of Clinical and Molecular Science, Università Politecnica delle Marche, Ancona, Italy
508PDF: 108 -
PO68 | Whole blood hypercoagulable profiles in a patient with markedly elevated lipoprotein(A) plasma levels and thrombotic complications: a case report C. Portinari, M. Biolo, A. Napolitano, L. Spiezia, A. Colpo, S. Zambon, A. Zambon, P. Simioni | Department of Medicine, Padova University Hospital, Padova, Italy
637PDF: 26 -
CO-29 | A RARE BLEEDING PRESENTATION IN MODERATE HEMOPHILIA A: PARAVESICAL HEMATOMA WITH PENOSCROTAL EXTENSION MIMICKING A UROLOGICAL EMERGENCY B. Stocco, C. Simion, E. Zanon, E. Dalla Porta, P. Simioni | Hemophilia Center, University Hospital of Padua, Italy
20PDF: 6 -
PO50 | Treatment with BTK inhibitors in patients affected by chronic lymphocytic leukemia: safety and hemostasis L. Gurgoglione, C.A. Piro, I. Scortechini, I. Battilà, M.C. Merlo, A. R. Scortechini, S. Rupoli, A. Poloni | Hematology Unit, AOU delle Marche-Università Politecnica delle Marche, Italy
515PDF: 14 -
CO-51 | HEMOSTATIC AND CARDIOVASCULAR PROFILES IN HEMOPHILIA PATIENTS WITH AND WITHOUT ATHEROSCLEROSIS A. Napolitano, E. Zanon, L. Spiezia, G. Camporese, P. Scarinzi, F. Ahmad, G. Saggiorato, C. Bulato, S. Toffanin, S. Gavasso, F. Sartorello, C. Simion, E. Campello, P. Simioni | Hemophilia Center, University Hospital of Padua, Italy
19PDF: 3 -
Diagnostic and management practices for inherited fibrinogen disorders: a nationwide survey of Italian Hemophilia Treatment Centers
906PDF: 117HTML: 121Supplementary: 78Appendix: 79 -
PO09 | Comparison of different aggregometry methods for evaluation of platelet function in patients with myeloproliferative neoplasms C. Fortino, I. Bertozzi, D. Regazzo, L. Gianesello, G. Nuozzi, F. Sartorello, V. Azzaro, G. Saggiorato, A. Bertomoro, P. Simioni | First Medical Clinic, Department of Medicine – DIMED, Università degli Studi di Padova, Italy
551PDF: 12 -
CO-68 | ACQUIRED FACTOR XIII DEFICIENCY ASSOCIATED WITH CROHN’S DISEASE: A CHALLENGING DIAGNOSTIC AND THERAPEUTIC CASE A. Colombo1, A. Dal Buono2|3, I. Quaglia1, C. Novembrino4, M.R. Fasulo1, C. Lodigiani1, M.E. Mancuso1|2 | 1Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy; 2Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, Italy; 3IBD Center, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy; 4Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Angelo Bianchi Bonomi, Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milano, Italy
20PDF: 4 -
PO24 | Emicizumab prophylaxis and bleeding outcomes: a single center clinical experience A. Taglietti1, S. Ligia1, F. Paoletti1, R. Mormile1, E. Baldacci2, A. Chistolini1, C. Santoro1,2 | 1Hematology, Department of Translational and Precision Medicine, Sapienza University of Roma; 2Hematology, Azienda Ospedaliera Universitaria Policlinico Umberto I, Roma, Italy
614PDF: 20 -
PO32 | ANTICOAGULANT THROMBOPROPHYLAXIS IN AGGRESSIVE LYMPHOMAS PATIENTS: PREDICTIVE THROMBOTIC RISK SCORES AND RISK FACTORS L. Gurgoglione1, G. Gini1, S. Rupoli1, A. Poloni1|2 | 1Hematology, AOU delle Marche, Ancona; 2Università Politecnica delle Marche, Ancona, Italy
494PDF: 95 -
PO76 | Thrombosis associated with midline in autoimmune patient: a case report on the use of apixaban in a real-world setting M.V. Cherchi, M. Anedda, S. Che, M. Vacca, M. Caboni, M. Mantega | Department of Internal Medicine, ASL Sulcis, Italy
589PDF: 26 -
PO32 | Effect of the sodium-glucose co-transporter-2 (SGLT2) inhibitors on platelet activation and lipid peroxidation: results of a pilot study P.G.M. Simeone1, R. Liani1, M. Alfonsetti1, B. Cancelli1, M. Frezza1, G. Raggiunti1, S. Zeeba2, F. Cipollone1, G. Renda2, F. Santilli1 | 1Department of Medicine and Aging Sciences, Center for Advanced Studies and Technology, University of Chieti; 2Department of Neuroscience, Imaging and Clinical Sciences, G. D’Annunzio University of Chieti-Pescara; 3University Cardiology Division, Heart Department, Policlinico SS Annunziata, Chieti, Italy
596PDF: 15 -
The landscape of rare coagulation factor deficiency management in Italy: a national hemophilia center survey
1340PDF: 215HTML: 133Appendix: 119 -
PO21 | PSYCHOLOGICAL IMPACT OF CANCER-ASSOCIATED THROMBOSIS: DUAL BURDEN AND IMPLICATIONS FOR QUALITY OF LIFE AND INTEGRATED PATIENT-CENTERED CARE G. Gerotziafas1|4, Y. Mitrou5, M. Marchetti6, P. Las Casa1, A. Tafur7, V. Bitsadze3, J. Khizroeva3, D. Taizhanova8, D. Antic9, C. Frére10, A. Makatsariya3, L. Garderet1|11, A. Escargueil1, C. Ay12, N. Lomatkin13, Z. Tazi-Mezalek14, M. Sassi15, M. Catalano4|16, J. Gligorov1|17, J. Caprini18, P. Van Dreden1|19, J. Fareed2, A. Falanga6 | 1Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology (UIC), Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP)Paris France; 2Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Chicago, USA; 3Thrombosis Center, Department of Obstetrics, Gynecology and Perinatal Medicine, The I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 4VAS-European Independent Foundation in Angiology/Vascular Medicine Milan Italy; 5Department of Phylosophy, National and Kapodistrian University of Athens, Greece; 6Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy. School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy; 7Vascular Medicine, Endeavor Health, Evanston, IL, USA; Pritzker School of Medicine, University of Chicago, Chicago, IL 60637, USA; 8Department of Internal Diseases, Karaganda Medical University Non-Commercial Joint Stock Company, Karaganda, Kazakhstan; 9Clinic for Hematology, University Clinical Center of Serbia, Faculty of Medicine University of Belgrade Belgrade Serbia; 10Department of Hematology, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, INSERM UMRS-1166 Institute of Cardiometabolism and Nutrition, Paris, France; 11Clinical Haematology Department, Sorbonne Université, Pitié-Salpêtrière Hospital, APHP, Paris; 12Department of Internal Medicine I, Clinical Division of Haematology and Haemostaseology, Medical University of Vienna, Vienna, Austria; 13Cardiology Division, Central Clinical Hospital of Presidential Administration, Moscow, Russia; 14Department of Internal Medicine, Hématologie Clinique, Centre Hospitalo-Universitaire Ibn Sina, Université Mohammed V de Rabat, Rabat, Morocco; 15Hematology Laboratory of Maternity and Neonatal Center of Monastir, Faculty of Pharmacy of Monastir, Monastir, Tunisia; 16Inter-University Research Center on Vascular Diseases, University of Milan-L Sacco Hospital, Milan, Italy; 17Medical Oncology Department, Tenon Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne University, Paris, France; 18Vascular Surgery, Pritzker School of Medicine at the University of Chicago, Chicago, USA; 19Clinical Research, Diagnostica Stago, Gennevilliers, France
441PDF: 93 -
CO-24 | BALANCING BLEEDING AND THROMBOSIS: SAFETY OF LOW-MOLECULAR-WEIGHT HEPARIN THROMBOPROPHYLAXIS IN PATIENTS WITH HEMOPHILIA UNDERGOING MAJOR SURGERY S. Bergonzi1|2|3, G. Murante1|2|3, M. Capetta1|2|3, F. Valeri1|2, C. Dainese1|2, A. Valpreda3|4, R. Pastorino3|4, F. Bocchi3|4, B. Bruno2|3, A. Borchiellini1|2 | 1Regional Centre for Hemorrhagic and Thrombotic Diseases, AOU Città della Salute e della Scienza, Torino, Italy; 2Division of Hematology, AOU Città della Salute e della Scienza, University of Turin, Italy; 3Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy; 4Central Laboratory Baldi and Riberi, AOU Città della Salute e della Scienza, University of Turin, Italy
21PDF: 4 -
OC11 | COMPLEXITIES IN MANAGING ANTITHROMBOTIC THERAPY IN PATIENTS WITH CANCER APPROACHING END-OF-LIFE: A MIXED METHOD INTEGRATION USING JOINT DISPLAY ANALYSIS E. Baddeley1, L. Van’t Walderveen2, H. Enggaard3, M. Søgaard4, D. Abbel2, S. Cannegieter2, M. Edwards1, C. Font5, J. Goedegebuur2, F.A. Klok2, K.J. Lifford1, I. Mahé6, S.P. Mooijaart2, S.I.R. Noble1, M. Pearson7, K. Seddon1, S. Sivell1, S. Szmit8, S Trompet2, A.A. Højen4 | 1Cardiff University, Cardiff, UK; 2Leiden University Medical Center, Leiden, The Netherlands; 3Aalborg University Hospital, Aalborg, Denmark; 4Aalborg University and Aalborg University Hospital, Aalborg, Denmark; 5Hospital Clinic Barcelona, Barcelona, Spain; 6Paris Cité Université, Paris, France; 7Hull York Medical School, Hull, UK; 8Centre of Postgraduate Medical Education, Warsaw, Poland
442PDF: 106 -
PO93 | Use of DOACS in heart transplantation recipients T. Marrazzo1, A. Delle Femine1, C. Amarelli2, R. Albisinni3 | 1UOC Medicina Interna e dei Trapianti, Ospedale Monaldi Azienda dei Colli, Napoli; 2UOSD CCH dei Trapianti, Ospedale Monaldi Azienda dei Colli, Napoli; 3UOC CCH Generale, Ospedale Monaldi Azienda dei Colli, Napoli, Italy
738PDF: 17
